Disease
12 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
SEP 9, 2026 · PHASE 1 TRIAL
ClinicalTrials.gov
This is a Phase 1, first-in-human study registration with no results posted; it describes planned enrollment and safety endpoints only, representing early-stage drug development.
AUG 19, 2026 · PHASE 1 TRIAL
ClinicalTrials.gov
This is a Phase 1 dose-escalation and dose-expansion trial registration with no results posted; it is a first-in-human safety and tolerability study designed to establish dosing, not efficacy.
This is a registry record for an ongoing observational study with no results reported; it describes a planned real-world evidence collection in HER2-low breast cancer but cannot yet support clinical conclusions.
AUG 17, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is a recruiting Phase 3 RCT registration with no reported results; the study design is sound but outcomes are not yet available, making it a planned trial rather than evidence of efficacy.
AUG 13, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is a registry record for an ongoing Phase 3 trial with no results yet reported; the study design is sound but evidence cannot be evaluated until data are available.
AUG 12, 2026 · INTERVENTIONAL STUDY
ClinicalTrials.gov
This is a registry record for a planned interventional study with no results posted; enrollment has not yet begun, making it a feasibility and safety assessment in an understudied population.
AUG 11, 2026 · OBSERVATIONAL STUDY
ClinicalTrials.gov
This is an active observational registry study with no reported results; it describes a planned real-world effectiveness evaluation in a specific population but carries no outcome data.
AUG 11, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
Early-phase, single-centre Phase 2 interventional study with small planned enrollment (n=15) examining a surrogate endpoint (hyperglycemia-free rate) in an exploratory design; results not yet reported in this registry record.